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Recent evidence has suggested that the initiation of antibody synthesis is a 
two-step process. The first step involves antigen phagocytosis and processing 
by macrophages (1,  2)  and the second step appears to consist of the transfer 
of  immunogenic information  from the macrophage to  the  immunocompetent 
cell with  subsequent  initiation  of antibody synthesis  (3). 
In  most  instances  immunological  immaturity  in  young  or  immunological 
deficiency in adult animals is attributed  to the absence of immunocompetent 
cells.  Recently however, it was reported by Gallily and Feldman (4)  that the 
immunological deficiency after  low  doses  of X-irradiation  could  be  restored 
by the  administration of macrophages. This suggests that the  immunological 
insult in adult mice by low doses of X-irradiation  is not directed against the 
immunocompetent  (antibody-synthesizing)  cell  but  is  directed  against  the 
antigen-recognizing or antigen-processing  cells,  namely the macrophages. 
In this paper we present evidence suggesting that immunological immaturity 
in  newborn mice  is  not  due  to  the  lack  of  antibody-synthesizing  (immuno- 
competent) cells but is due, at least in part, to the lack of antigen-recognizing 
or antigen-processing cells, in the form of competent macrophages. This evidence 
was obtained by transplanting adult macrophages into newborn mice and find- 
ing  that  this  enhanced  the  rate  of  immunological  maturation  to  sheep  red 
blood cell antigens. 
Materials and Methods 
Adult C3H/He mice were purchased from the Jackson Memorial Laboratory, Bar Harbor, 
Me. Newborn mice were obtained from our own colony of C3H/He mice which were originally 
acquired from the Jackson  Memorial Laboratory  and  maintained  by brother  and  sister 
matings. Skin grafts can be freely exchanged between our C3H mice and the C3H/He mice 
obtained from Bar Harbor. All mice were housed in humidified, air-conditioned rooms. They 
were fed a Purina diet, fortified with occasional portions of dried milk and oats. 
Treatment of Mavrophage DoTwrs--Peritoneal macrophages were provoked in adult mice by 
intraperitoneal  injection of 3-ml sterile thioglycoUate medium. The thioglycollate (Difco 
Laboratories, Detroit, Mich.) was prepared by adding 2.98 g powder to 100-ml cold distilled 
water and dissolved by heating to boiling point. After autoclaving the medium in tightly 
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capped tubes for 20 min at 15 lb. pressure, it was stored for I wk in the dark at room tempera- 
ture. Once prepared the thioglycollate could be used for at least 2 wk if stored at 4°C. 
6  or 7 days after thioglycollate injection, peritoneal cells were collected by washing the 
peritoneal cavity with 3  ml of Hanks' balanced salt solution (BSS)  containing heparin (10 
units/1 ml) and 1% inactivated calf serum. Peritoneal cells were placed in plastic centrifuge 
tubes and kept cold during the collection period. All steps were carried out under sterile con- 
ditions. Cells were counted in a hemacytometer using 0.5% acetic add as a diluent. Viability 
was checked with the dye exclusion method, using 0.5% eosin in saline. Differential cell counts 
were carried out with 1% crystal violet in 0.1 ~t citric acid (5). Previously (5) we have reported 
that we can harvest 15-20 million peritoneal cells from each thioglycollate-treated mouse. The 
peritoneal cell population consists of 86% large macrophages, 5% medium-sized cells,  7% 
small lymphocytes, and 2% polymorphonudear leukocytes and mast cells.  For the sake of 
convenience we will, in this paper, use the terms macrophage and peritoneal cell interchangea- 
bly keeping in mind, however, that we are not dealing with a  homogeneous population of 
peritoneal cells. 
Spleen cell suspensions were prepared in sterile phosphate-buffered saline by pressing the 
tissue through a stainless steel sieve (6). 
Treatment of Macrophage or Spleen Cell Recip/ents.--Young  mice  were  injected  intra- 
peritoneally with varying doses of peritoneal macrophages or spleen cells from adult donors. 
Injections  were carried out in 0.05-0.1 ml volumes with a 30 gauge needle and collodion applied 
to the injection site to prevent leakage. Only litters of seven or eight mice were used for these 
experiments since we found that the normal rate of immunological maturation varies con- 
siderably with litter size.  Litters were divided in groups of two  mice, each injected  with a 
different dose of cells and marked by clipping the toes or tip of the tail. In some experiments 
the cells were rendered nonviable by heat treatment at 60°C.  One group of two control mice, 
from each litter, was not treated with cells. 
Simultaneously with the maerophage treatment, or 3 days after macrophage or spleen cell 
treatment, all young mice were injected intraperitoneally with l0  T (0.05 ml of I%), l0  s (0.05 
ml of 10%), or 109 (0.1 ml of 50%) sheep red blood cells (SRBC), washed three times with 
sterile saline. After injection the mice were returned to their mothers and each litter kept in a 
separate cage for the remainder of the experiment. An adult mouse, positive control for the 
plaque test, was injected intraperitoneally with los (0.5 ml of 10%) SRBC. 
Determination of Antibody-Producing Calls.--4 days after SRBC administration the mice 
were sacrificed and the number of antibody-producing cells in their spleens determined with 
the Jeme plaque test (7). 1 day prior to the assay, 10 ml of 1.4% agar (Dffco)  in phosphate- 
buffered saline (PBS), containing 0.05% DEAE-dextran, was poured into 10-era  disposable 
Petri dishes. The plates were stored, upside down, in a plastic bag in the refrigerator. On the 
day of the assay the mice were sacrificed and a spleen cell suspension prepared from each group 
by pressing the tissues through a 50 mesh stainless steel screen into sterile PBS. The cells were 
washed once and suspended in a total volume of 0.5 ml. Cells were counted in a hemacytom- 
eter using 0.5% acetic acid. Spleen cells, together with 0.1 ml of a 20% washed SRBC suspen- 
sion, were  added to small tubes containing 2  mi of  0.6%  Agamse  (L'Industrie Biologique 
Francaise, Gennevilliers, Seine, France) in PBS and kept at 48°C in a  water bath. A  small 
amount of dextrose (0.4%) added to the Agarose solution, was found to increase the plating 
efficiency of immunized spleen cells. The contents of each small tube was mixed with a Vortex 
mixer and poured over the prewarmed bottom agar layer in the large Petri dishes. Three plates 
were prepared for each spleen cell suspension. Plate 1 received 0.2 ml of the spleen cells and 
plates 2 and 3 received 0.1 ml of the spleen cells.  80% of each cell suspension was therefore 
assayed for the presence of antibody-forming cells.  Spleen cells were added to the Agarose 
with a  0.2 ml micropipette calibrated at 0.1 ml volume. As positive control, two plates were 
prepared with 2 million spleen cells, obtained from the adult immunized mouse. BERTIE  ~'.  ARGYRIS  461 
All plates were incubated at 37°C for 2 hr. At this time 1.5 ml of reconstituted guinea pig 
complement (Gibco,  lyophillzed, diluted  1:10 in PBS) was added to each plate and reincu- 
bated for an additional hour. The plates were stained with benzidine (6) and stored overnight 
at 4°C. The next day the plaques were counted under a dissecting microscope (magnification 
of 7) using a grid as background. The number of antibody-forming ceils was determined by 
calculating the number of plaque-forming cells per  I  million spleen cells.  The increase in 
TABLE I 
Number  of Plaque-Forming  Cells  (PFC) in  Spleens  of C3H Mice  Treated  with Adult  C3H 
Maorophages  (Mdp) and Simultaneously  Sensitized  with l0  s SRBC 
Age of  No. of M~  No. litters 
recipients  injected 
days 
1 
No. mice 
injected* 
No. cells 
in spleen 
(X Io  e) 
No. PFC/1 X 10g spleen  cells 
E  C  E  C  E  C  E/C  P 
20 X  10  s  5  9  8  16  7  0.5  0.9  0.6  >0.05 
10X10  s  4  8  6  23  8  0.5  1.1  0.4  >0.05 
5 X  106  4  8  6  15  8  0.6  0.7  0.9  >0.05 
20X 106  4  8  8  37  26  1.0  0.7  1.4  >0.05 
10 X  106  5  13  12  22  19  0.7  0.3  2.3  >0.05 
5 X  106  5  9  10  25  19  0.5  0.5  1.0  >0.05 
20 X  10  e  4  8  8  36  37  0.6  0.4  1.5  >0.05 
10 X  106  6  13  13  38  26  2.0  0.7  2.8  <0.01 
5 X  106  6  11  11  48  30  0.9  0.6  1.5  >0.05 
20 X  106  5  10  10  51  45  1.1  2.7  0.4  >0.05 
10 X  10  s  6  13  12  52  45  2.6  2.6  1  >0.05 
5 )< 106  5  10  9  51  46  2.6  3.2  0.8  >0.05 
20 X  106  3  4  6  70  43  7.8  14.5  0.5  >0.05 
10 X  106  6  12  12  63  38  8.7  10.0  0.9  >0.05 
5 X  10  s  6  11  11  52  39  10.2  12.0  0.8  >0.05 
* E, experimental; C, control. 
number of antibody-producing cells after experimental treatment was expressed as a ratio of 
plaque-forming cells between experimental and control groups. Statistical analysis was based 
on rank correlation, as described by the Mann-Whitney U test (8). The null hypothesis was 
rejected if P  was smaller than 0.05. 
RESULTS 
Effect of Simultaneous Administration  of Adult C3H Macrophages and SRBC 
to Young C31t M/ce.--Table I records the effect of simultaneous administration 
of adult C3H peritoneal macrophages and 10  s SRBC on antibody production 
in 1-, 2-, 3-, 5-, and 8-day-old C3H mice. 1- and 2-day-old mice fail to respond 
significantly to macrophage and SRBC treatment. 3-day-old mice respond to 462  MACROPHAGES  AND  IMMUNOLOGICAL  MATURATION 
10 million macrophages as indicated by a slight but significant increase in the 
number of plaque-forming cells.  20 or 5 million macrophages, injected into 3- 
day-old mice have no significant effect. Peritoneal macrophages injected into 
5-  or 8-day-old C3H mice fail to enhance antibody production  significantly. 
Peritoneal macrophages also exert a proliferative stimulus as indicated by the 
increased number of cells in the spleen of macrophage-treated mice. 
From these data we can conclude that there is a  critical stage in develop- 
ment  during  which  the  lymphoid cells  of young mice  can  benefit from  the 
addition  of adult  peritoneal macrophages.  Macrophage  treatment before  or 
beyond this stage is ineffective. The data also suggest that the enhancement 
of immunological maturation  in  young mice  after macrophage  treatment  is 
TABLE  II 
Number of Pique-Forming  Calls (PFC) in Spleens of C3tt Mice Treated at Birth 
with Adult C31t Macropkages (MRS) and Sensitized with 10' SRBC 3 Days Later 
No. of Mq~  No. litters 
injected 
20 X  106  7 
10 X  106  7 
5  X  10  6  9 
2.5  ×  106  5 
No. mice 
injected 
No. cells 
in spleen 
(× tO  e) 
No. PFC/I X  10s spleen ceils 
E  C  E  C  E  C  E/C  P  value 
13  14  42  32  1.3  0.4  32  0.036 
14  16  67  37  3.5  0.5  7.0  0.019 
18  20  50  36  2.4  0.4  6.0  0.01 
10  11  51  39  0.5  0.2  2.5  >0.05 
dose dependent. Both these points will  receive further attention later in this 
paper. 
Effect of Prior Administration of Adult C31t Macropkages on Antibody Response 
of Young C31t Mice to SRBC.--In the previous experiments we have shown 
that the spleen cells of 3-day-old C3H mice respond most favorably to macro- 
phage treatment. In those experiments macrophages and SRBC were adminis- 
tered simultaneously. In order to give the transplanted macrophages a chance 
to adjust  to  their new  environment before being called into action we pre- 
treated  1-day-old  C3H  mice  with  adult  C3H  peritoneal  macrophages  and 
challenged these macrophage-treated mice 3  days later with  SRBC.  The re- 
suits, recorded in Table II, illustrate a considerable increase in the number of 
plaque-forming  cells  (PFC)  after  transplantation  of  5  or  10  million  adult 
macrophages. It is interesting that a  higher dose of maerophages, namely 20 
million,  is  less  effective than  a  lower dose,  suggesting  the  importance  of  a 
critical ratio of macrophages to immunocompetent cells.  A dose of 2.5 million 
macrophages appears subthreshold and is ineffective in stimulating antibody 
production significantly.  In  four groups  of mice,  macrophage  treatment  re- 
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Role of Antigen Dose in Enhancement of Immunological Maturation in Young 
Mice  by  Adult  Macrophages.--The  previous  experiment  suggests  that  pre- 
treatment with macrophages is more effective in stimulating antibody produc- 
tion to SRBC in young mice than simultaneous administration of macrophages 
and  SRBC.  We  therefore adopted  this routine in our further  studies.  In  the 
TABLE III 
Number of Plaque-Forming Cells (PFC) in Spleens of C3H Mice Treated at Birth with 
10 X  10  6  Adult C3tt Macropkages and Sensitized 3 Da, ~s Later with I0  ~, 10  8, or 10  9  SRBC 
No. of  SRBC  No. litters 
10  7  4 
10  s  7 
109  4 
No. mice 
injected 
No. cells  in 
spleen 
(X 106) 
No. PFC/I X 106 spleen cells 
E  C  E  C  E  C  E/C  P 
7  7  44  36  0.2  0.4  0.5  >0.05 
14  16  67  37  3.5  0.5  7.0  0.019 
8  7  39  31  3.3  0.1  33  0.01 
TABLE IV 
Number oJ Plaque-Forming Cells (PFC) in Spleens of C3tI Mice Treated at 3 or 5 Days with 
Adult C3H Macrophages (Md)) and Sensitlmt with 10  8 SRBC 3 Days Later 
Age of  No. of MO 
recipients 
days 
3  20  X  106 
10  X  106 
5X  106 
5  20 X  I06 
10  X  10  e 
5X  10  6 
No. litters 
injected 
No. mice 
injected 
E  C 
10  11 
13  13 
12  13 
9  11 
14  15 
7  9 
No.  cells  in 
spleen 
(X lO  e)  No. PFC/! X 106 spleen cells 
c  E/C 
1.5 
0.4 
0.5 
0.3 
0.4 
0.4 
E  C 
66  44 
58  40 
63  44 
66  64 
75  65 
53  56 
E 
6.2  4.2 
1.7  3.7 
1.6  3.2 
4.3  12.3 
5.6  14.0 
7.1  16.2 
P value 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
present  experiments  we  treated  1-day-old C3H  mice  with  10  million adult 
C3H macrophages and sensitized them 3 days later with l0  T, 10  a, or 109 SRBC. 
The  results,  recorded in Table III, demonstrate  that  an  antigen dose of  l0  T 
SRBC is insufficient to demonstrate the enhancement of immunological matura- 
tion by macrophage treatment. Dosages of 10  s or 109 SRBC are equally effec- 
tive in stimulating antibody synthesis in macrophage-treated mice. The very 
high ratio of PFC in the group treated with 109 SRBC is a  reflection of the low 
number  of PFC  in  the control, noumacrophage-treated group. This could be 
the result of immunological tolerance induced by the high dose of antigen. To 464  M.ACROPHAGES  AND  IMMUNOLOGICAL  M.ATURATION 
avoid any complications as a result of immunological tolerance, we selected an 
antigen dose of 108 SRBC for our further experiments. 
Effect of Macrophage Treatment in 3- and 5-Day-Old Mice.--In the previous 
experiment we have seen that macrophage treatment of 1-day-old C3H mice, 
followed 3 days later by injection of SRBC,  results in an enhanced antibody 
response. In the current experiments we have transplanted adult C3H peritoneal 
cells  into  3-  and  5-day-old  C3H  mice.  The  results,  recorded  in  Table  IV, 
illustrate  that  the  immunocompetence of spleen  cells  from  3-  or  5-day-old 
C3H mice"'is  not enhanced by macrophage treatment  (P > 0.05). The trans- 
TABLE V 
Number of Plaque-Forming Cells (PFC) in Spleens of  C3H Mice Treated at Birth with 10 X  10  ~ 
Ileal-Killed Macrophages (Mc~) or Spleen Cells and Sensitized 3 Days Later with  I0  8 SRBC 
Cell-type 
injected 
M~ 
Spleen 
Heat treatment 
60°C-I hr 
60oc-~ 
None 
60°C-I hr 
60°C-~ hr 
None 
No. litters 
injected 
6 
6 
10 
No. mice 
injected 
EIc 
!-- 
11  11 
15  12 
17  19 
1010 
8  6 
13  12 
No. cells 
in  spleen 
(X  lO s) 
E  C 
46  39 
45  36 
49  39 
4,3  36 
35  43 
41  40 
No. PFC/1 X I0  e  spleen  cells 
E  C  E/C  P value 
1.1  0.8  1.4  >0.05 
0.7  0.6  1.1  >0.05 
1.7  0.6  2.8  <0.05 
0.7  0.6  1.2  >0.05 
1.0  0.7  1.4  >0.05 
2.4  0.7  3.4  <0.05 
planted macrophages  do stimulate  spleen  cell  proliferation in  the-3-day-old 
group of mice. 
Effect of Nonviable Macrophages and Spleen  Cells on Antibody  Response of 
Neonatal  C3tt Mice to SRBC.--The  effect of nonviable,  heat-killed cells on 
immunological maturation in newborn mice is illustrated in Table V. 10 million 
macrophages or spleen cells, heated for ~,~ or 1 hr at 60°C are unable to increase 
the immune response of baby mice to SRBC. Nonheated spleen ceils or macro- 
phages in the control groups are effective. A  comparison between the data in 
Tables II,  III,  and V  indicates a  decrease in  the  effectiveness of 10 million 
viable macrophages. In hindsight we think this is due to the occasional use of 
old macrophage donors in the later experiments. Preliminary results indicate 
that macrophages from older mice are less effective in the enhancement of im- 
munological maturation. 
DISCUSSION 
The experiments described in this paper were designed to test the hypothesis 
that newborn mice are immunologically deficient, not because they lack func- BERTIE  F.  ARGYRIS  465 
tional immunocompetent cells, but because they lack an antigen recognition or 
processing mechanism, in the form of functional macrophages. The hypothesis 
received  experimental  support  by  demonstrating  that  transplantation  of 
adult viable  peritoneal  macrophages  into newborn  mice allows these macro- 
phage-treated mice  to  respond  immunologically  to  SRBC  antigens.  There 
appears  a  critical  period  in the development  of the mouse during which the 
lymphoid cells can be stimulated immunologically by macrophage  treatment. 
The lack of response before this period may be ascribed  to a functional im- 
maturity of the immunocompetent cells. The failure of macrophages to enhance 
antibody response beyond this critical period could be due to the fact that the 
mice, at this stage,  have developed  their own functional antigen recognition 
or  antigen-processing  mechanism and  additional  transplantation of macro- 
phages has no effect. 
In C3H mice,  the above mentioned critical  period  resides around the 3rd 
day after birth. Enhancement of immunological maturation can be demon- 
strated  when macrophages  and  SRBC  are  administered simultaneously to 
3-day-old  C3H mice, but the enhancement is more pronounced if 1-day-old 
C3H mice are pretreated with adult macrophages  and sensitized 3 days later 
with  SRBC.  The  pretreatment may give  the  transplanted  macrophages  a 
chance to settle and adapt to their new environment before being called up for 
functional duty. It should be kept in mind that the critical period during which 
young mice respond to macrophage  treatment may vary from strain to strain. 
Braun and Lasky (9) have reported  that macrophage  treatment of 2-day-old 
C57BL mice results  in an increased immune response to SRBC. 
It should also be kept in mind that we do not claim that macrophage treat- 
ment brings  the neonatal mouse up to the level of adult immunocompetence. 
We simply feel that the adult macrophages allow for the expression of func- 
tional  activity of  those  immunocompetent cells which  the  neonatal mouse 
possesses. It is clearly obvious that during postnatal development the number 
of immunocompetent cells increases with time. A critical ratio of macrophage 
to immunocompetent cells at each stage during development may be impor- 
tant for the initiation of an immune response. This is possibly the reason why 
macrophage  treatment of 3- or 5-day-old C3H mice fails to increase the anti- 
body response  to SRBC and why high  doses (20 million)  of peritoneal  cells 
implanted into the 1-day-old C3H  mouse are less effective than smaller (5 or 
10 million) doses in the enhancement of immunological maturation. 
In this paper we have used the terms peritoneal cell and macrophage inter- 
changeably.  The thioglycollate-induced  peritoneal  cells, used in these experi- 
ments, consist of 86 % macrophages,  5 % medium-sized mononuclear  cells, 7 % 
small lymphocytes, and 2 % polymorphonuclear  cells and mast cells. There is 
good  indication  that the increase  in number of antibody-producing cells in 
neonatal mice after treatment with peritoneal  cells is not due to the passive 466  MACROPHAGES AND  IMMUNOLOGICAL MATIYRATION 
transfer of immunocompetent cells.  First of all, we have shown previously (5) 
that peritoneal cells from thioglycollate-treated mice fail to transfer adoptive 
immunity to X-irradiated recipient mice (10). Secondly, if the immunocompe- 
tant cells in the spleens of the neonatally treated mice were of donor origin, 
one would expect an increase in number when larger quantities of peritoneal 
cells are  transferred to newborn mice. This proved not to be the case. As  a 
matter of fact higher numbers (20 million) of peritoneal cells are less effective 
in the enhancement of immunological maturation than doses of 5 or 10 million. 
Subthreshold  doses  of macrophages  (2.5  million)  are  also  ineffective. This 
suggests a critical ratio of macrophage to immunocompetent cell for the success- 
ful induction of antibody synthesis. An inhibitory action of large numbers of 
macrophages on immunocompetent cells has also been reported by Harris (11). 
Nonviable,  heat-killed  macrophages  or  spleen  cells  appear  ineffective  in 
enhancing immunological maturation to SRBC. This suggests that the stimu- 
lation of antibody production is dependent on the functional activity of the 
transplanted cells.  This is also supported by our preliminary finding that  10 
million macrophages from old donor mice fail to enhance antibody production 
to  SRBC  in  neonatal  C3H  mice.  Occasionally,  however, we  do  get  erratic 
results  and find  stimulation  of antibody production  in  neonatal  mice  after 
treatment with heated macrophages. We are not sure, at the moment, whether 
in  these instances  the macrophages have not been  completely killed by  the 
heat treatment or whether during the heat treatment a  stimulatory factor is 
released which on occasion can stimulate antibody production in young mice. 
Adult viable macrophages appear to enhance antibody synthesis as well as 
stimulate spleen cell proliferation. We do not know whether these two phenom- 
ena are brought about by the same mechanism. We have found that spleen cell 
proliferation  and  increase  in  number  of  antibody-synthesizing  cells  after 
macrophage treatment are not always correlated. We are currently testing the 
effect of adjuvants  on  immunological maturation,  in  the  hope  of getting  a 
better understanding of this relationship. 
We are suggesting, at least for the moment, that macrophage treatment of 
neonatal mice supplies the young animal with an antigen recognition or anti- 
gen-processing system. It should be kept in mind, however,  that this  may be 
an over-simplification of a complex situation. There are other possible explana- 
tions for the above observed results. Only further experiments will allow us to 
get a better understanding of the role of macrophages in immunological matura- 
tion. 
S~4.R¥ 
1.  Transplantation of peritoneal macrophages from thioglycollate-stimulated 
adult C3H donor mice, into 3-day-old C3H mice results in an enhanced anti- 
body  response  to  simultaneously  injected  SRBC.  The  increase  in  immuno- BERTIE  ~'.  ARGYRIS  467 
competence is even more pronounced when 1-day-old C3H mice are pretreated 
with  adult macrophages and  sensitized 3  days later with  SRBC.  Nonviable 
macrophages or nonviable spleen cells are ineffective. 
2.  There is a critical period in the development of the neonatal mouse during 
which the spleen cells benefit from the addition of adult macrophages. Treat- 
ment before or beyond this stage is ineffective. 
3.  Very high doses (20 million) of macrophages are less effective in stimulat- 
ing antibody synthesis to SRBC than doses of 5 or 10 million, suggesting that a 
critical ratio of macrophages to immunocompetent cells may be required for 
enhancing antibody synthesis in young mice. 
4.  The results  are  discussed  in  the light  of  the hypothesis  that  newborn 
mice are  immunologicaUy deficient not because they lack immunocompetent 
cells but because they lack an antigen recognition or antigen-processing system 
in the form of functional macrophages. 
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